Insider · CIK 0001585699
Sharon Mates
ceochairofficerdirector
Files at ITCI (Intra-Cellular Therapies, Inc.), BNTC (Benitec Biopharma Inc.). First filing Dec 6, 2024, latest Dec 6, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $8.7M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Intra-Cellular Therapies, Inc. | $8.7M 102,697 shares | -9% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 5, 2024 | ITCI Intra-Cellular Therapies, Inc. | 51,697 0.05% of outstanding | $4.3M | Dec 5, 2024 | $4.4M |
| Dec 4, 2024 | ITCI Intra-Cellular Therapies, Inc. | 51,000 0.05% of outstanding | $4.4M | Dec 4, 2024 | none |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | BNTC Benitec Biopharma Inc. | AGrant or award Options (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jan 26, 2026 |
| Dec 1, 2025 | BNTC Benitec Biopharma Inc. | AGrant or award Options (right to buy)derivative | +3,500 | $0.00 | $0 | 3,500 | Dec 3, 2025 |
| Nov 5, 2025 | BNTC Benitec Biopharma Inc. | AGrant or award Options (right to buy)derivative | +28,517 | $0.00 | $0 | 28,517 | Nov 7, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Common Stock | -945,235 | $132.00 | $125M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Common Stockindirect: By the Sharon Mates Family Foundation | -190,000 | $132.00 | $25M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -86,003 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -135,399 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -138,473 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -66,886 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -53,471 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -50,167 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -40,713 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -69,940 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -121,212 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Performance Stock Unitsderivative | +40,712 | $0.00 | $0 | 40,712 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Performance Stock Unitsderivative | -40,712 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Performance Stock Unitsderivative | +34,970 | $0.00 | $0 | 34,970 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Performance Stock Unitsderivative | -34,970 | - | - | 0 | Apr 2, 2025 |
| Mar 26, 2025 | ITCI Intra-Cellular Therapies, Inc. | GGift Common Stock | -190,000 | $0.00 | $0 | 945,235 | Mar 31, 2025 |
| Mar 26, 2025 | ITCI Intra-Cellular Therapies, Inc. | GGift Common Stockindirect: By the Sharon Mates Family Foundation | +190,000 | $0.00 | $0 | 190,000 | Mar 31, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +40,712 | - | - | 1,144,646 | Mar 10, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -19,848 | $131.19 | $2.6M | 1,124,798 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +20,566 | - | - | 1,145,364 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -10,129 | $131.24 | $1.3M | 1,135,235 | Mar 10, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -40,712 | $0.00 | $0 | 40,713 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -20,566 | $0.00 | $0 | 0 | Mar 10, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +34,969 | - | - | 1,120,912 | Mar 4, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -16,978 | $128.20 | $2.2M | 1,103,934 | Mar 4, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -34,969 | $0.00 | $0 | 69,940 | Mar 4, 2025 |
| Jan 31, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Common Stock | +30,847 | $0.00 | $0 | 1,101,176 | Feb 4, 2025 |
| Jan 31, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -15,233 | $127.00 | $1.9M | 1,085,943 | Feb 4, 2025 |
| Feb 3, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Restricted Stock Unitsderivative | +121,212 | $0.00 | $0 | 121,212 | Feb 4, 2025 |
| Dec 4, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +51,000 | $12.73 | $649k | 1,121,329 | Dec 6, 2024 |
| Dec 4, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -27,667 | $85.62 | $2.4M | 1,093,662 | Dec 6, 2024 |
| Dec 4, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -23,333 | $86.00 | $2.0M | 1,070,329 | Dec 6, 2024 |
| Dec 5, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +51,697 | $12.73 | $658k | 1,122,026 | Dec 6, 2024 |
| Dec 5, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -50,163 | $84.06 | $4.2M | 1,071,863 | Dec 6, 2024 |
| Dec 5, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -1,534 | $84.69 | $130k | 1,070,329 | Dec 6, 2024 |
| Dec 4, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -51,000 | $0.00 | $0 | 51,697 | Dec 6, 2024 |
| Dec 5, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -51,697 | $0.00 | $0 | 0 | Dec 6, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.